Genworth Posts $0.11 Q3 Loss as Long-Term Care Charges and a $150M Tax Valuation Allowance Bite
GNW is trading near its 52-week low of $7.84 (14% above the low).
Summary
Genworth lost $41 million, or $0.11 a share, in Q3 2026 as long-term care reserve charges deepened, the legacy RBC ratio fell to about 274% and a $150 million tax valuation allowance was booked; management warned the Q4 assumption review could be materially unfavorable.
Key Events · Earnings and Guidance · GNW
-
Q3 Swings to $0.11 Loss
Net loss available to common stockholders was $41 million, or $(0.11) per diluted share, versus net income of $116 million ($0.28) a year earlier; adjusted operating income excluding Closed Block was $102 million vs $113 million.
-
Long-Term Care Charges Deepen
Closed Block adjusted operating loss widened to $146 million from $96 million, and the long-term care liability remeasurement loss reached $264 million for the nine months versus $145 million, driven by lower terminations and higher claims.
-
RBC Ratio Falls to ~274%
The consolidated risk-based capital ratio of the legacy insurance subsidiaries dropped to approximately 274% from 300% at December 31, 2025, mainly on a statutory loss in long-term care.
-
$150M Tax Valuation Allowance
An additional $150 million valuation allowance on capital deferred tax assets was recorded through OCI in Q3 2026, lifting the total allowance to $702 million from $545 million.
Analysis · GNW · Finance
The headline is a $41 million quarterly loss, down from $116 million of income a year ago, but the real damage sits in the Closed Block. Long-term care drove a $264 million liability remeasurement loss for the nine months versus $145 million, and the segment's adjusted operating loss widened to $146 million from $96 million. Two balance-sheet items matter more than the headline. The legacy insurance subsidiaries' risk-based capital ratio fell to roughly 274% from 300% at year-end, and the company added $150 million to its valuation allowance on capital deferred tax assets through OCI because rising rates shrank unrealized gains available to offset capital losses. Management also pre-flagged that the fourth-quarter annual assumption review could be materially unfavorable, largely on long-term care cost-of-care inflation and utilization — the next hard datapoint for this story. Enact remains the cash engine, with a 158% PMIERs sufficiency ratio and $122 million of capital returned in the quarter, and buybacks continued into October.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNW was trading at $8.91 on NYSE in the Finance sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $7.84 to $10.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.